ADMA/SDMA in Elderly Subjects with Asymptomatic Carotid Atherosclerosis: Values and Site-specific Association

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2014 Apr 18

PMID 24739810

Citations 8

Authors

Graziano Riccioni

Luca Scotti

Nicolantonio DOrazio

Sabina Gallina

Giuseppe Speziale

Lorenza Speranza

Tonino Bucciarelli

Affiliations

Soon will be listed here.

Abstract

Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase (NOS) inhibitor known as a mediator of endothelial dysfunction and atherosclerosis. Circulating ADMA levels are correlated with cardiovascular risk factors such as hypercholesterolemia, arterial hypertension, diabetes mellitus, hyperhomocysteinemia, age and smoking. We assessed the relationship between ADMA values and site-specific association of asymptomatic carotid atherosclerosis (intima-media thickness (CIMT) and plaque) in elderly subjects. One hundred and eighty subjects underwent a complete history and physical examination, determination of serum chemistries and ADMA levels, and carotid ultrasound investigation (CUI). All subjects had no acute or chronic symptoms of carotid atherosclerosis. Statistical analyses showed that high plasma levels of ADMA/SDMA were positively correlated to carotid atherosclerosis (CIMT and plaque) (p<0.001), with significant site-specific association. Total cholesterol, low density lipoprotein cholesterol, triglycerides and C-reactive protein plasma concentrations were significantly associated with asymptomatic carotid atherosclerosis (p<0.001). High serum concentrations of ADMA and SDMA were associated with carotid atherosclerotic lesions as measured by CIMT ad plaque and may represent a new marker of asymptomatic carotid atherosclerosis in elderly subjects.

Citing Articles

SDMA as a marker and mediator in cerebrovascular disease.

Riddell A, Flynn A, Bergugnat H, Dowsett L, Miller A Clin Sci (Lond). 2024; 138(20):1305-1323.

PMID: 39391895 PMC: 11479986. DOI: 10.1042/CS20241021.

Arginine Derivatives in Cerebrovascular Diseases: Mechanisms and Clinical Implications.

Grosse G, Schwedhelm E, Worthmann H, Choe C Int J Mol Sci. 2020; 21(5).

PMID: 32150996 PMC: 7084464. DOI: 10.3390/ijms21051798.

The protective effect of dronedarone on the structure and mechanical properties of the aorta in hypertensive rats by decreasing the concentration of symmetric dimethylarginine (SDMA).

Quintana-Villamandos B, Gonzalez M, Delgado-Martos M, Gutierrez-Arzapalo P, Boger R, Luneburg N PLoS One. 2019; 14(5):e0216820.

PMID: 31112581 PMC: 6529158. DOI: 10.1371/journal.pone.0216820.

Age-dependent effects of homocysteine and dimethylarginines on cardiovascular mortality in claudicant patients with lower extremity arterial disease.

Jud P, Hafner F, Verheyen N, Gary T, Meinitzer A, Brodmann M Heart Vessels. 2018; 33(12):1453-1462.

PMID: 29946762 PMC: 6267409. DOI: 10.1007/s00380-018-1210-9.

The issue of plasma asymmetric dimethylarginine reference range - A systematic review and meta-analysis.

Nemeth B, Ajtay Z, Hejjel L, Ferenci T, Abram Z, Muranyi E PLoS One. 2017; 12(5):e0177493.

PMID: 28494019 PMC: 5426758. DOI: 10.1371/journal.pone.0177493.

References

Xia W, Shao Y, Wang Y, Wang X, Chi Y . Asymmetric dimethylarginine and carotid atherosclerosis in Type 2 diabetes mellitus. J Endocrinol Invest. 2012; 35(9):824-7. DOI: 10.1007/BF03347101. View

Nanayakkara P, Teerlink T, Stehouwer C, Allajar D, Spijkerman A, Schalkwijk C . Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int. 2005; 68(5):2230-6. DOI: 10.1111/j.1523-1755.2005.00680.x. View

Dimitroulas T, Sandoo A, Kitas G . Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases. Int J Mol Sci. 2012; 13(10):12315-35. PMC: 3497274. DOI: 10.3390/ijms131012315. View

Chirinos J, David R, Bralley J, Zea-Diaz H, Munoz-Atahualpa E, Corrales-Medina F . Endogenous nitric oxide synthase inhibitors, arterial hemodynamics, and subclinical vascular disease: the PREVENCION Study. Hypertension. 2008; 52(6):1051-9. DOI: 10.1161/HYPERTENSIONAHA.108.120352. View

Boger R . Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med. 2006; 38(2):126-36. DOI: 10.1080/07853890500472151. View

Mohan S, Fung H . Mechanism of cellular oxidation stress induced by asymmetric dimethylarginine. Int J Mol Sci. 2012; 13(6):7521-7531. PMC: 3397541. DOI: 10.3390/ijms13067521. View

de Jong S, Teerlink T . Analysis of asymmetric dimethylarginine in plasma by HPLC using a monolithic column. Anal Biochem. 2006; 353(2):287-9. DOI: 10.1016/j.ab.2006.03.010. View

Lu T, Ding Y, Lin S, Lee W, Tai H . Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J. 2003; 24(21):1912-9. DOI: 10.1016/j.ehj.2003.08.013. View

Sandoo A, Dimitroulas T, Veldhuijzen van Zanten J, Smith J, Metsios G, Nightingale P . Lack of association between asymmetric dimethylarginine and in vivo microvascular and macrovascular endothelial function in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2012; 30(3):388-96. View

10.

Chen S, Li N, Deb-Chatterji M, Dong Q, Kielstein J, Weissenborn K . Asymmetric dimethyarginine as marker and mediator in ischemic stroke. Int J Mol Sci. 2013; 13(12):15983-6004. PMC: 3546674. DOI: 10.3390/ijms131215983. View

11.

Mittermayer F, Krzyzanowska K, Exner M, Mlekusch W, Amighi J, Sabeti S . Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol. 2006; 26(11):2536-40. DOI: 10.1161/01.ATV.0000242801.38419.48. View

12.

Zoccali C . Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int. 2006; 70(1):26-33. DOI: 10.1038/sj.ki.5000417. View

13.

Honda O, Sugiyama S, Kugiyama K, Fukushima H, Nakamura S, Koide S . Echolucent carotid plaques predict future coronary events in patients with coronary artery disease. J Am Coll Cardiol. 2004; 43(7):1177-84. DOI: 10.1016/j.jacc.2003.09.063. View

14.

Franceschelli S, Ferrone A, Pesce M, Riccioni G, Speranza L . Biological functional relevance of asymmetric dimethylarginine (ADMA) in cardiovascular disease. Int J Mol Sci. 2013; 14(12):24412-21. PMC: 3876119. DOI: 10.3390/ijms141224412. View

15.

Davis P, Dawson J, RILEY W, Lauer R . Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation. 2001; 104(23):2815-9. DOI: 10.1161/hc4601.099486. View

16.

Riccioni G, Bucciarelli V, Scotti L, Aceto A, D Orazio N, Di Ilio E . Relationship between asymmetric dimethylarginine and asymptomatic carotid atherosclerosis. J Biol Regul Homeost Agents. 2010; 24(3):351-8. View

17.

Furuki K, Adachi H, Enomoto M, Otsuka M, Fukami A, Kumagae S . Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: six-year prospective study using carotid ultrasonography. Hypertens Res. 2008; 31(6):1185-9. DOI: 10.1291/hypres.31.1185. View

18.

Krempl T, Maas R, Sydow K, Meinertz T, Boger R, Kahler J . Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J. 2005; 26(18):1846-51. DOI: 10.1093/eurheartj/ehi287. View

19.

Schott L, Wildman R, Brockwell S, Simkin-Silverman L, Kuller L, Sutton-Tyrrell K . Segment-specific effects of cardiovascular risk factors on carotid artery intima-medial thickness in women at midlife. Arterioscler Thromb Vasc Biol. 2004; 24(10):1951-6. DOI: 10.1161/01.ATV.0000141119.02205.6b. View

20.

Zoccali C, Benedetto F, Maas R, Mallamaci F, Tripepi G, Malatino L . Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol. 2002; 13(2):490-496. DOI: 10.1681/ASN.V132490. View